Summary The extracellular matrix protein tenascin (TN) is overexpressed in a number of solid tumours. This, however, is the first study to examine TN expression in ovarian tumours. TN protein was examined in frozen sections of 50 human ovarian tumours by immunohistochemistry. Malignant and borderline tumours showed a significantly greater incidence and intensity of stromal staining than benign tumours (P<0.0001 and P=0.038 respectively). Seven omental metastases were also examined and showed a strikingly similar protein distribution to their primary tumour counterparts. The expression pattern of different RNA isoforms, created by alternative splicing of the primary transcript, was identified using reverse transcription-polymerase chain reactions (RT-PCR). The smallest TN RNA splice variant (284 bp) was found in all tumours examined, while the appearance of larger molecular weight transcripts (-490 and 556 bp), as major forms, was predominantly limited to malignant tumours, with 9/12 malignant tumours showing this pattern compared with 1/6 benign tumours. These data suggest that malignant ovarian tumours have increased expression of TN compared with benign tumours and this may be associated with induction of specific isoforms.
Tenascin (TN) is a large hexameric glycoprotein found in the extracellular matrix (Chiquet-Ehrismann et al., 1986; Erickson and Bourdon, 1989) . Each monomer of the homohexamer consists of five components: a central domain, heptad repeats, epidermal growth factor (EGF)-like repeats, fibronectin type III repeats and a fibrinogen-like sequence. Several different isoforms of the monomeric protein have been identified ranging in molecular weight from 150 to 320 kDa. These isoforms are produced by alternative splicing of the primary RNA transcript of the domain with fibronectin type III repeats (Jones et al., 1989; Gulcher et al., 1989) . In cultured human cell lines, eight different mRNA species, containing varying numbers of fibronectin type III repeats, have been identified (Siri et al., 1991; Sriramarao and Bourdon, 1993) . The larger isoforms of TN are often associated with rapidly proliferating and migrating cells (Borsi et al., 1992) .
TN is expressed transiently in developing tissues in embryos and is absent or greatly reduced in adults. In general, TN can be found in areas associated with cellular proliferation and tissue reorganisation, for example, during wound healing in human skin (Latijnhouwers et al., 1994) and in breast tissue during gestation and lactation (Howeedy et al., 1990) . TN expression also varies in normal breast tissue depending on the stage of the menstrual cycle (Ferguson et al., 1990) and is overexpressed in the stroma of breast cancer (Mackie et al., 1987) and other solid tumours (Zagag et al., 1995; Ibrahim et al., 1993; Yamada et al., 1992; Natali et al., 1991; Koukoulis et al., 1991; Vollmer et al., 1990) . It has been proposed that production of TN is under paracrine control; several growth factors, including transforming growth factor beta (TGF-fl), have been implicated in regulation of TN expression (Pearson et al., 1988 In the section of normal ovary, the observed staining was limited to a fine line around the smooth muscle cells of blood vessels with negligible reaction in the surrounding ovarian stroma (Figure 2a) . TN staining was observed in 48 of the 50 tumours at variable levels (Table 1) . While all staining was in the extracellular space, the staining pattern could be classified as either focal or diffuse. In focal staining the immunoreactivity was confined to structures such as blood vessels (Figure 2b) , as in the normal ovary. In sections demonstrating diffuse staining, in addition to the perivascular staining, TN expression was observed throughout large regions of the stroma (Figure 2c ). The intensity of such staining was arbitrarily classified as strong, moderate or weak. Heterogeneity was observed within sections of individual tumours and where it was observed the score allocated was based upon a combination of area stained and intensity of the reaction.
The incidence and intensity of diffuse stromal staining is shown in Tables I and II (Figure 2d ). Incidence of these bands varied between tumour types. Thus, the 284 bp band appeared to be a constant feature of all the tumour samples, while the relative proportions of the other bands varied between tumours. We believe the occasional appearance of double bands at the 284 bp position is artefactual. While the intensity of bands cannot be compared directly between tumours, because of the nonquantitative nature of the PCR reaction, the relative intensity of the bands within each tumour sample may be compared across samples. Most apparent was that in 9/12 (75%) malignant tumours there was increased intensity of the -490 and 556 bp bands, compared with the 284 bp band. In only one out of six (17%) benign tumours were these two bands present at relatively high intensity; in the majority of benign tumours and the normal ovary sample these bands were either totally absent or greatly reduced compared with the 284 bp species. The benign tumour which did contain the -490 and 556 bp bands was the teratoma. There is a statistically significant difference between the malignant and benign expression patterns (75% vs 17%), giving a P-value of 0.043 by Fisher's exact test.
Discussion
These studies represent the first in which TN expression has been observed at the level of mRNA and protein in a series of ovarian tumours. We have been able to show differences, in pattern of immunohistochemical staining and species of RNA expressed, between malignant and benign tumours.
Benign tumours show a pattern of protein expression which is similar to that seen in normal ovary, with TN limited to focal expression around blood vessels. The presence of TN in the walls of blood vessels in ovarian tissue was also noted by Tamura et al. (1993) . In malignant and borderline tumours TN was also detected throughout the tumour stroma, while malignant tumours displayed the greatest intensity of stromal staining. These findings are consistent with those made in other solid malignant tumours, in which there is overexpression of TN in the stroma. These observations on protein expression were consistent with the presence of TN RNA. RT -PCR detected TN RNA in all tumours examined. However, differences were seen in the premRNA splicing pattern between malignant and benign tumours. Benign tumours showed a pattern similar to that found in normal ovary. In malignant tissue there was increased expression particularly of the -490 and 556 bp products. The band observed at -490 bp had not been previously described by Sirn et al. (1992 (Borsi et al., 1994 (Borsi et al., , 1995 .
The function of TN in vivo is not yet understood. Notably, TN has been shown to inhibit cell adhesion to fibronectin (Chiquet-Ehrismann et al., 1988) ' and the TN molecule has been shown to contain an anti-adhesive signal. Further investigations have shown that TN also contains a site that promotes cell adhesion (Spring et al., 1989) . These properties, combined with the observations that TN is involved in the migration of cells during development of embryonic tissues and the migration of keratinocytes in skin wounds (Latijnhouwers et al., 1994) , leads to speculation that the overexpression of TN in tumours may be involved in the invasion process (Riedl et al., 1995; Ishihara et al., 1995) .
In all the tumours examined, the immunoreactivity was strongest at epithelial-mesenchymal junctions. This observation could have a number of explanations: (1) the TN may be accumulating in the basement membrane of these regions as would be expected with other extracellular matrix proteins;
(2) tumour cells could themselves be producing TN; or (3) the fibroblasts in malignant tumours may be inherently different from those in benign tumours in their capacity to express TN. This pattern of expression is also consistent with the hypothesis that production of TN is under paracrine control; experimental data from model systems (Pearson et al., 1988) showed that TGF-# can increase TN expression in chick embryo fibroblasts, and Chiquet-Ehrismann et al. (1989) showed that MCF-7 cells can induce production of TN in fibroblasts via TGF-fl. Other growth factors have been examined and found capable of inducing TN synthesis. These include bFGF (Tucker et al., 1993) , activin (Umbhauer et al., 1992) and various combinations of cytokines (Rettig et al., 1994) . The role of growth factors, hormones and cytokines in regulating TN production is currently being addressed using cell lines.
In conclusion, we have demonstrated that TN may be expressed both at the level of protein and RNA in malignant and benign ovarian tumours. However, the malignant tumours show increased stromal expression of TN and a different RNA splicing pattern. The significance of these findings warrants further investigation.
